Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 81Observational 1Expanded_access 1

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Melanoma 1Glioma 1Glioblastoma 1

Interventions

3-Iodobenzylguanidine 9TIC10 compound 3vorasidenib 1ulixertinib 1tucatinib 1tovorafenib 1rindopepimut 1pembrolizumab 1pegfilgrastim 1paclitaxel-Angiopep-2 conjugate 1omburtamab I-131 1mogamulizumab 1mirdametinib 1gallium maltolate 1fluorodopa F 18 1efineptakin alfa 1carbon-11 methionine 1avapritinib 1Vorinostat 1Vaccination 1Proton Pump Inhibitors 1Potassium Iodide 1OKN 007 1Methionine 1Ketoconazole 1Ipilimumab 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Fenretinide 1Eflornithine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × pembrolizumab × CNS × Clear all
NCT03311542 2018-01-10

Expanded Access for Pembrolizumab (MK-3475)

Center Trials & Treatment

No longer available
CNSDermatologic

Glioblastoma, Glioma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡